FI3982960T3 - Perinnöllisen angioödeeman hoitoja - Google Patents

Perinnöllisen angioödeeman hoitoja Download PDF

Info

Publication number
FI3982960T3
FI3982960T3 FIEP20734283.3T FI20734283T FI3982960T3 FI 3982960 T3 FI3982960 T3 FI 3982960T3 FI 20734283 T FI20734283 T FI 20734283T FI 3982960 T3 FI3982960 T3 FI 3982960T3
Authority
FI
Finland
Prior art keywords
compound
formula
solvate
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
FIEP20734283.3T
Other languages
English (en)
Finnish (fi)
Inventor
Edward Paul Feener
Sally Louise Marsh
Andreas Maetzel
Michael David Smith
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Application granted granted Critical
Publication of FI3982960T3 publication Critical patent/FI3982960T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
FIEP20734283.3T 2019-06-14 2020-06-15 Perinnöllisen angioödeeman hoitoja FI3982960T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861725P 2019-06-14 2019-06-14
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema
PCT/GB2020/051439 WO2020249977A1 (en) 2019-06-14 2020-06-15 Treatments of hereditary angioedema

Publications (1)

Publication Number Publication Date
FI3982960T3 true FI3982960T3 (fi) 2023-08-29

Family

ID=67700145

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20734283.3T FI3982960T3 (fi) 2019-06-14 2020-06-15 Perinnöllisen angioödeeman hoitoja

Country Status (34)

Country Link
US (1) US20220218680A1 (enExample)
EP (2) EP4282474A3 (enExample)
JP (3) JP7356518B2 (enExample)
KR (1) KR102748728B1 (enExample)
CN (1) CN114126612A (enExample)
AR (1) AR119158A1 (enExample)
AU (1) AU2020293614B2 (enExample)
BR (1) BR112021024664A2 (enExample)
CA (1) CA3142218A1 (enExample)
CL (2) CL2021003244A1 (enExample)
DK (1) DK3982960T3 (enExample)
EA (1) EA202193019A1 (enExample)
ES (1) ES2956471T3 (enExample)
FI (1) FI3982960T3 (enExample)
GB (1) GB201910116D0 (enExample)
HR (1) HRP20230696T1 (enExample)
HU (1) HUE063163T2 (enExample)
IL (1) IL288615A (enExample)
LT (1) LT3982960T (enExample)
MA (1) MA56187B1 (enExample)
MD (1) MD3982960T2 (enExample)
MX (1) MX2021014557A (enExample)
MY (1) MY205687A (enExample)
PH (1) PH12021552966A1 (enExample)
PL (1) PL3982960T3 (enExample)
PT (1) PT3982960T (enExample)
RS (1) RS64412B1 (enExample)
SG (1) SG11202113304YA (enExample)
SI (1) SI3982960T1 (enExample)
SM (1) SMT202300261T1 (enExample)
TW (1) TW202112370A (enExample)
UA (1) UA129869C2 (enExample)
WO (1) WO2020249977A1 (enExample)
ZA (1) ZA202110685B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2022084693A1 (en) * 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
EP4291186A1 (en) 2021-02-09 2023-12-20 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
ES2991820T3 (es) 2022-04-27 2024-12-05 Kalvista Pharmaceuticals Ltd Formulaciones de un inhibidor de la calicreína plasmática
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
CN105452240B (zh) 2013-05-23 2018-06-26 卡尔维斯塔制药有限公司 杂环衍生物
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema

Also Published As

Publication number Publication date
SMT202300261T1 (it) 2023-09-06
US20220218680A1 (en) 2022-07-14
KR102748728B1 (ko) 2024-12-30
HUE063163T2 (hu) 2023-12-28
AU2020293614A1 (en) 2022-01-27
UA129869C2 (uk) 2025-08-27
JP2023166406A (ja) 2023-11-21
WO2020249977A1 (en) 2020-12-17
CA3142218A1 (en) 2020-12-17
DK3982960T3 (da) 2023-08-21
PL3982960T3 (pl) 2024-01-15
SG11202113304YA (en) 2021-12-30
JP2025124716A (ja) 2025-08-26
SI3982960T1 (sl) 2023-10-30
EP3982960B1 (en) 2023-06-28
EP4282474A2 (en) 2023-11-29
IL288615A (en) 2022-02-01
EA202193019A1 (ru) 2022-03-24
KR20220024220A (ko) 2022-03-03
EP3982960A1 (en) 2022-04-20
PH12021552966A1 (en) 2022-07-25
BR112021024664A2 (pt) 2022-05-31
JP2022536287A (ja) 2022-08-15
RS64412B1 (sr) 2023-09-29
EP4282474A3 (en) 2024-02-14
PT3982960T (pt) 2023-09-26
CL2023000639A1 (es) 2023-10-30
JP7356518B2 (ja) 2023-10-04
ZA202110685B (en) 2024-06-26
MX2021014557A (es) 2022-01-11
HRP20230696T1 (hr) 2023-10-13
MA56187B1 (fr) 2023-09-27
LT3982960T (lt) 2023-08-25
GB201910116D0 (en) 2019-08-28
CN114126612A (zh) 2022-03-01
ES2956471T3 (es) 2023-12-21
TW202112370A (zh) 2021-04-01
AR119158A1 (es) 2021-12-01
MA56187A (fr) 2022-04-20
JP7688078B2 (ja) 2025-06-03
MY205687A (en) 2024-11-06
CL2021003244A1 (es) 2022-09-30
AU2020293614B2 (en) 2024-08-15
MD3982960T2 (ro) 2023-12-31
NZ782935A (en) 2025-02-28

Similar Documents

Publication Publication Date Title
FI3982960T3 (fi) Perinnöllisen angioödeeman hoitoja
RU2004129324A (ru) Применения бисфосфоновых кислот для лечения и профилактики остеопороза
JP2011168580A (ja) 医薬組成物
JPH0920659A (ja) 炎症性腹部疾患のためのカッパ−アヘン製剤作働薬
JP2016507500A5 (enExample)
CN102036669A (zh) 用于治疗早泄的药物组合物
JPWO2020249977A5 (enExample)
US3557292A (en) Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine
JP2011079854A (ja) 洞房結節If電流阻害剤およびアンギオテンシン変換酵素阻害剤の新規な組み合わせならびにそれを含む医薬組成物
US20180125792A1 (en) Non-steroidal anti-inflammatory drugs for cough
US20080194877A1 (en) Benzamidine Derivatives for Treatment and Prevention of Cancer Therapy Induced Mucositis
Shao et al. Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone
JPWO2020249979A5 (enExample)
US20150079183A1 (en) Lercanidipine Hydrochloride and Losartan Potassium Compound Preparation and Preparation Method Thereof
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
NZ782935B2 (en) Treatments of hereditary angioedema
RU2412701C2 (ru) Способ снижения непереносимости противотуберкулезных препаратов
US5876751A (en) Antispasmodic and antinflammatory composition and a process for the manufacture thereof
CA2612179A1 (en) A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion
CN100409850C (zh) 2h-[1,3]-噁嗪并[3,2-a]吲哚衍生物在制备治疗神经性疼痛的药物中的用途
NO333599B1 (no) Anvendelse av distrontiumsalter av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre for fremstillingen av medikamenter for behandlingen av gastro-duodenal smerte
CN1076195C (zh) 含有锌化合物和对乙酰氨基苯乙酸的组合物
EP1611901B1 (en) Preventive or remedy for teeth grinding
EP0868915A1 (en) An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium